Waggie Pet Zone

How Veterinary NSAIDs Differ

Traditional NSAIDs inhibit cyclooxygenase enzymes (COX-1 and COX-2):

• COX-1 supports essential homeostatic functions like stomach lining protection, platelet aggregation, and renal blood flow.
• COX-2 is primarily induced by tissue injury and drives pain and inflammation.

Modern veterinary medications are formulated to preferentially or selectively target COX-2 (or bypass COX enzymes entirely to hit specific downstream prostaglandin receptors), maximizing pain control while minimizing damage to the gut, liver, and kidneys.

Carprofen (Rimadyl, Novox, Quellin)

• Primary Uses: Post-surgical pain (orthopedic and soft-tissue) and chronic osteoarthritis.
• Efficacy: High. Decades of clinical use make it the standard benchmark for post-op recovery and joint pain.
• Safety: Well-tolerated overall. Potential side effects include mild-to-moderate gastrointestinal upset and rare idiosyncratic liver toxicity. Baseline and routine blood chemistry profiles (every 3 to 6 months) are required.
• Cost: Low to Moderate. Widespread generic availability makes carprofen one of the most budget-friendly daily options.

Meloxicam (Metacam)

• Primary Uses: Osteoarthritis flare-ups, acute musculoskeletal injuries, and short-term post-op pain. (Also used off-label in feline medicine under strict, micro-dosed protocols or as a single perioperative injection).
• Efficacy: High. Formulated frequently as a palatable liquid suspension, allowing precise weight-based titration for small dogs.
• Safety: Moderate. Preferentially targets COX-2, but can precipitate gastric ulceration or renal stress if dosed inaccurately or administered to dehydrated patients.
• Cost: Low to Moderate. Readily available as an affordable generic.

Grapiprant (Galliprant)

• Primary Uses: Canine Osteoarthritis (mild, moderate, and severe). Note: Not labeled or effective for acute post-surgical pain or oncology.
• Efficacy: Moderate to High for chronic arthritic stiffness.
• Safety: Highest GI and renal safety profile. Galliprant is an EP4 prostaglandin receptor antagonist (PRA) rather than a COX inhibitor. It blocks only the specific receptor mediating OA pain and inflammation while leaving both COX-1 and COX-2 enzymes active to protect the gut and kidneys.
• Cost: High. Brand-name exclusivity makes ongoing daily administration costly.

Deracoxib (Deramaxx) & Firocoxib (Previcox)

• Primary Uses: Post-operative orthopedic surgery, chronic osteoarthritis, and increasingly, veterinary oncology.
• Efficacy: Very high. Both are COX-2 selective, providing robust anti-inflammatory coverage for severe joint disease and high-trauma surgical repairs (such as TPLO or cruciate stabilization).
• Safety: Good. By sparing COX-1, they generally carry a reduced risk of gastric mucosal erosion compared to older non-selective NSAIDs, though standard renal and GI precautions remain necessary.
• Cost: Moderate to High.

Oncology Focus: Deramaxx for TCC / UCC

Transitional Cell Carcinoma (TCC)—also known as Invasive Urothelial Carcinoma (UCC/InvUC)—is the most common cancer of the canine urinary bladder. Canine TCC cells strongly overexpress the COX-2 enzyme, meaning COX inhibition does not just control local pain and dysuria; it actively halts tumor proliferation and induces apoptosis (cancer cell death).

While non-selective piroxicam was long the standard medical choice, studies led by veterinary oncologists (notably from Purdue University’s comparative oncology group) have evaluated deracoxib (Deramaxx) as an effective, better-tolerated therapy for TCC/UCC:

• Antitumor Efficacy: Clinical trials demonstrate that deracoxib alone achieved disease control (tumor shrinkage or stable disease without progression) in over 85% of dogs with established TCC, with a median survival time exceeding 320 days.
• Early-Stage Intervention: Newer screening and early-intervention trials in high-risk breeds (such as Scottish Terriers) showed that initiating deracoxib at early detection stages yielded an objective remission rate (complete + partial remission) of 42%, outperforming historical averages for late-stage interventions.
• Tolerability Advantage: Because deracoxib selectively spares COX-1, it significantly reduces the incidence of severe stomach ulceration and renal strain frequently seen with lifelong, non-selective piroxicam therapy.

Piroxicam (Feldene)

• Primary Uses: Oncology protocols, particularly bladder/urethral TCC, prostatic carcinoma, and oral squamous cell carcinomas.
• Efficacy: Proven historical track record as an antitumor and palliative agent.
• Safety: Low / High Risk. As an older non-selective COX inhibitor, it carries a high risk of stomach ulcers and GI bleeding. Pets often require co-administration with gastroprotectants (like omeprazole or misoprostol) alongside strict monitoring.
• Cost: Low. Inexpensive generic human medication compounded for veterinary patients.